Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of 2017 A/H7N9 IIV With or Without AS03 Adjuvant
NCT03738241Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2018
- Primary completion
- Jun 2020
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised trial of monovalent inactivated influenza A/H7N9 virus vaccine in Avian Influenza (AI) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Mean Titers of Serum Hemagglutination Inhibition Antibodies at Day 22, Geometric Mean Titers of Serum Neutralizing Antibodies at Day 22 and 8 more. Started Dec 2018; status: completed.
02
Drugs
monovalent inactivated influenza A/H7N9 virus vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT03738241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03738241.